Tag: CureVac

The biotechnology firm CureVac is approaching its final days as a publicly traded company on the NASDAQ. The acquisition by ...

A significant deadline has arrived for one of Germany's most closely watched biotech narratives. The offer period for BioNTech's exchange ...

Time is running out for investors in CureVac, the former mRNA pioneer, as a critical deadline approaches. The company's acquisition ...

The curtain is closing on CureVac's independent presence in the stock market. Following a conclusive shareholder decision this week, the ...

Time is running out for investors in CureVac as the company's independence draws to a close. The German biopharmaceutical firm, ...

The independent existence of CureVac as a publicly traded company is drawing to a close. Following decisive shareholder approval, the ...

CureVac investors have officially cleared the path for the company's acquisition by vaccine developer BioNTech, bringing months of anticipation to ...

CureVac is preparing to conclude its journey as an independent entity, but not before delivering a significant financial surprise. As ...

The future of Tübingen-based biotech firm CureVac hangs in the balance as the company approaches a critical juncture. With operational ...

The countdown has begun for CureVac's final days as an independent publicly traded company. A special shareholder meeting scheduled for ...